Richard Glynne
Private Equity Investor at Versant Venture Management LLC
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Hans Jörg Reinhardt | M | 68 | 40 years | |
| Clare Ozawa | M | 50 |
Inception Sciences, Inc.
 Inception Sciences, Inc. Pharmaceuticals: MajorHealth Technology Inception Sciences, Inc. provides small molecule pharmaceutical incubator services. Its focus is on creating therapies with transformative potential to address diseases and disorders. The company creates new companies in partnership with pioneering academic researchers and major biopharmaceutical companies, which provide funding and a path to liquidity through pre-negotiated acquisitions. The company was founded in 2011 and is headquartered in San Diego, CA.
Versant Venture Management LLC
 Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | 13 years |
| Peppi Prasit | M | - |
Inception Sciences, Inc.
Inception Sciences, Inc. Pharmaceuticals: MajorHealth Technology Inception Sciences, Inc. provides small molecule pharmaceutical incubator services. Its focus is on creating therapies with transformative potential to address diseases and disorders. The company creates new companies in partnership with pioneering academic researchers and major biopharmaceutical companies, which provide funding and a path to liquidity through pre-negotiated acquisitions. The company was founded in 2011 and is headquartered in San Diego, CA.
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | 13 years |
| Robin Praeger | M | - |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | 24 years |
| Bill Winters | M | 62 | 11 years | |
| Steven Edelson | M | - |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | 8 years |
| Samir Shah | M | 63 | 20 years | |
| Christine Mathews | F | - |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | 18 years |
| Nancy Andrews | M | 65 | 9 years | |
| Charles Sawyers | M | 65 | 11 years | |
| Vasant Narasimhan | M | 48 | 19 years | |
| Mehmet Badur | M | - |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | 2 years |
| Thomas Woiwode | M | 52 |
Inception Sciences, Inc.
Inception Sciences, Inc. Pharmaceuticals: MajorHealth Technology Inception Sciences, Inc. provides small molecule pharmaceutical incubator services. Its focus is on creating therapies with transformative potential to address diseases and disorders. The company creates new companies in partnership with pioneering academic researchers and major biopharmaceutical companies, which provide funding and a path to liquidity through pre-negotiated acquisitions. The company was founded in 2011 and is headquartered in San Diego, CA.
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | 22 years |
| Bradley Bolzon | M | 64 |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | - |
| Brian Busser | M | - |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | 3 years |
| Rachel F. Lane | M | - |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | 4 years |
| Cathy Dring | F | - |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | - |
| Joel Drewry | M | - |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | - |
| Katharina Kreymborg | M | - |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | 2 years |
| Rami Hannoush | M | - |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | 1 years |
| Simon Brown | M | - | 11 years | |
| Richard Van Doren | M | - |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | - |
| Lev Osherovich | M | - |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | - |
| Carlo Rizzuto | M | 53 |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | 12 years |
| Shane Mulligan | M | - |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | - |
| Elizabeth Alcamo | F | - |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | 4 years |
| Charlotte Pamer-Wieser | M | - | 13 years | |
| Stephan Kontos | M | - |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | 2 years |
| Thomas Quertermous | M | 71 |
Stanford University
| 27 years |
| Benjamin Cravatt | M | 54 |
Inception Sciences, Inc.
Inception Sciences, Inc. Pharmaceuticals: MajorHealth Technology Inception Sciences, Inc. provides small molecule pharmaceutical incubator services. Its focus is on creating therapies with transformative potential to address diseases and disorders. The company creates new companies in partnership with pioneering academic researchers and major biopharmaceutical companies, which provide funding and a path to liquidity through pre-negotiated acquisitions. The company was founded in 2011 and is headquartered in San Diego, CA. | - |
| Mark Blumenkranz | M | 73 |
Stanford University
| 27 years |
| Linda Armstrong | M | 61 | 17 years | |
| Peter Emtage | M | - |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | 3 years |
| Audrey MacLean | F | - |
Stanford University
| 27 years |
| Kirk Nielsen | M | 50 |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | 18 years |
| Richard D. van Doren | M | 47 |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | 2 years |
| Max Eisenberg | M | - |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | 5 years |
| Fritz Prinz | M | 74 |
Stanford University
| 30 years |
| James R. Swartz | M | - |
Stanford University
| 26 years |
| Alicia Levey | M | - |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | 1 years |
| Nigel Sheail | M | 59 |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | 1 years |
| Markus Warmuth | M | 53 |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | 4 years |
| Markus Enzelberger | M | 55 |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | 4 years |
| Gianni Gromo | M | - |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | 11 years |
| Nikita Sharma | F | - |
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jeremy S. Caldwell | M | 55 |
Inception Sciences, Inc.
Inception Sciences, Inc. Pharmaceuticals: MajorHealth Technology Inception Sciences, Inc. provides small molecule pharmaceutical incubator services. Its focus is on creating therapies with transformative potential to address diseases and disorders. The company creates new companies in partnership with pioneering academic researchers and major biopharmaceutical companies, which provide funding and a path to liquidity through pre-negotiated acquisitions. The company was founded in 2011 and is headquartered in San Diego, CA.
Stanford University
| 11 years |
| Ronen Tamir | M | 57 | - | |
| Raj Atluru | M | 54 |
Stanford University
| 10 years |
| Wendelin Wiedeking | M | 72 | 11 years | |
| Aaron Partridge | M | - |
Stanford University
| 10 years |
| Rolf M. Zinkernagel | M | 80 | 15 years | |
| Joseph Jimenez | M | 64 | 11 years | |
| Gary Sutton | M | - |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | 16 years |
| Enrico Cipro Vanni | M | 73 | - | |
| Susanne Antonie Schaffert | M | 57 | 2 years | |
| Alex Kunczynski | M | - |
Stanford University
| 5 years |
| Ashley Johnson | F | 52 |
Stanford University
| 6 years |
| Juan Andres | M | 59 | 12 years | |
| Dimitri Azar | M | 65 | 7 years | |
| Peter Kornicker | M | - | 20 years | |
| Mauria Finley | F | 50 |
Stanford University
| 5 years |
| David ibnAle | M | 52 |
Stanford University
| 5 years |
| Douglas Flanzer | M | - |
Stanford University
| 5 years |
| Verena A. Briner | M | 72 | 3 years | |
| Cipora Herman | F | 50 |
Stanford University
| 5 years |
| Stephen van Horne | M | - |
Stanford University
| 2 years |
| Jennifer Wu | F | - |
Stanford University
| 9 years |
| Jon Koplin | M | - |
Stanford University
| 5 years |
| Justin Wilson | M | 42 |
Stanford University
| 5 years |
| Adam Nash | M | - |
Stanford University
| 5 years |
| Elizabeth Loboa | M | 57 |
Stanford University
| 7 years |
| Jené Elzie | F | 49 |
Stanford University
| 5 years |
| Tim Roughgarden | M | - |
Stanford University
| 5 years |
| Erica Malin | F | - |
Stanford University
| 4 years |
| Patrick Yue | M | - |
Stanford University
| 5 years |
| Benjamin Chelf | M | - |
Stanford University
| 6 years |
| Ghazi Al-Rawi | M | - |
Stanford University
| 6 years |
| Laura Shawver | M | 66 |
Phenomix Corp.
 Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | 8 years |
| Ann Marie Fudge | F | 72 | - | |
| Philip Satre | M | 74 |
Stanford University
| 4 years |
| William Brody | M | 80 | - | |
| Daniel Vasella | M | 70 | 17 years | |
| Alexandre F. Jetzer-Chung | M | 83 | 15 years | |
| Kevin Linker | M | - |
Stanford University
| 7 years |
| Kevin Efrusy | M | 51 |
Stanford University
| 5 years |
| Alex Scherbakovsky | M | - |
Stanford University
| 4 years |
| Ziang Tony Ngo | M | 45 |
Stanford University
| 4 years |
| Andreas von Planta | M | 68 | - | |
| Shannon Klinger | M | 53 | 10 years | |
| Christopher C. Goodnow | M | - |
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | 8 years |
| Hung Hoang | M | - |
Stanford University
| 3 years |
| Ravi Belani | M | - |
Stanford University
| 4 years |
| Tom Perkins | M | - |
Stanford University
| 3 years |
| Robert Kalman | M | - |
Stanford University
| 6 years |
| David Lam | M | - |
Stanford University
| 5 years |
| Kay Luo | F | - |
Stanford University
| 6 years |
| Thomas Wellauer | M | 69 | - | |
| Mun Tak Yang | F | 70 | - | |
| Sameer Dholakia | M | 50 |
Stanford University
| 4 years |
| Ahmed Farooq | M | - |
Stanford University
| 6 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 73 | 73.00% |
| Switzerland | 28 | 28.00% |
| United Kingdom | 0 | -.--% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Richard Glynne
- Personal Network
